Welcome to our dedicated page for INTERPACE BIOSCIENCES SEC filings (Ticker: IDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpace Biosciences, Inc. filings document material-event disclosures for a thyroid-focused molecular diagnostics company. Recent 8-K reports furnish operating results and financial-condition updates tied to Interpace Diagnostics and its commercial thyroid testing franchise, including disclosures related to ThyGeNEXT and ThyraMIRv2.
The company’s regulatory filings also record capital-structure developments, including repayment of its term loan facility with BroadOak Capital Partners and conversion of Series C Preferred Stock into common stock. These disclosures provide formal records of results releases, Regulation FD communications, debt obligations, equity structure and business updates following the company’s transition away from PancraGEN.
INTERPACE BIOSCIENCES, INC. (IDXG) approved and is implementing a 1-for-5 reverse stock split of its common stock. Stockholders authorized the board on August 20, 2026 to choose a ratio between 1:2 and 1:10, and the board set the final ratio at 1-for-5.
The reverse split becomes effective at 12:01 a.m. Eastern Time on August 27, 2026, when every five shares of common stock will be combined into one share, with no change to the $0.01 par value. Approximately 27.7 million shares outstanding will become approximately 5.5 million, while authorized shares remain unchanged, increasing potential headroom.
Fractional shares will not be issued and will instead be rounded up to the nearest whole share. The stock is expected to begin trading on a split-adjusted basis on OTCID on August 27, 2026, temporarily under ticker IDXGD for 20 trading days, with a new CUSIP of 46062X402. The company states the reverse split is primarily intended to help meet Nasdaq Capital Market minimum bid price requirements for a proposed uplisting.
Interpace Biosciences, Inc. (IDXG) filed an amended current report to document stockholder approval and adoption of its new 2026 Benefit Plans. At the August 20, 2026 annual meeting, stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan.
The 2026 Equity Incentive Plan replaces the company’s 2019 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan replaces the 2019 Employee Stock Purchase Plan, as amended. No further equity awards will be granted under the 2019 Equity Incentive Plan and no further purchases will occur under the 2019 ESPP. Detailed terms of the new plans are provided in the company’s July 7, 2026 definitive proxy statement and in plan forms incorporated by reference as exhibits.
INTERPACE BIOSCIENCES, INC. (IDXG) reported the results of its 2026 annual meeting of stockholders held on August 20, 2026. Stockholders approved all matters submitted to a vote, including the election of directors and several additional proposals.
Directors Vijay Aggarwal, Thomas W. Burnell, Joseph D. Keegan, Ph.D., Fortunato Ron Rocca, and Stephen J. Sullivan each received over 24.4 million votes in favor, with no votes against and between 135,575 and 808,652 votes withheld, plus 1,347,136 broker non-votes for each nominee.
INTERPACE BIOSCIENCES, INC. (IDXG) reported equity compensation and related share movements for CEO, President & Chairman Thomas W. Burnell. On August 20, 2026 he was granted 1,966,763 Restricted Stock Units (RSUs), each representing one share of common stock, all of which vested upon grant and included additional RSUs intended to cover tax obligations. These RSUs converted into common stock, and 581,718 shares were returned to the company to satisfy tax withholding obligations, with Burnell receiving the remaining shares. He also received a grant of 554,018 stock options with a strike price of $2.02 per share, vesting in four equal annual installments beginning August 20, 2027 and expiring August 20, 2036. Separately, 10,885 shares of common stock are reported as held indirectly by his spouse.
INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.
INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.
INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.
INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.
INTERPACE BIOSCIENCES, INC. (IDXG) reported equity compensation transactions for CFO & COO Christopher McCarthy on August 20, 2026. He was granted 554,018 RSUs, of which 277,009 vested immediately and converted into common stock, with 277,009 RSUs scheduled to vest on August 20, 2027, subject to continued service. He also received a stock option for 277,009 shares of common stock at an exercise price of $2.02 per share, expiring August 20, 2036, vesting in four equal annual installments beginning August 20, 2027. After these transactions, he directly held 323,800 shares of common stock.
Interpace Biosciences reported Q2 2026 results showing improved profitability and margins as a thyroid-only diagnostics business. Revenue was $9.1 million, down 1% from $9.2 million reported a year earlier but up 9% from $8.4 million on a Pro Forma basis excluding the discontinued PancraGEN® business. Gross profit margin rose to 62% from 57% reported and 54% Pro Forma, and operating income was $0.3 million compared with operating losses in the prior-year quarter. Income from continuing operations was $0.3 million versus a $0.5 million loss a year ago.
Adjusted EBITDA increased to $0.7 million, or 8% of revenue, from $0.2 million on a Pro Forma basis, aided by higher thyroid revenue and efficiency gains, despite approximately $0.2 million of non-recurring professional fees. For the first six months of 2026, revenue was $18.2 million, up 12% from the prior-year Pro Forma period, with a 64% gross margin and $1.1 million of income from continuing operations. Adjusted EBITDA for the half-year was $2.3 million, or 13% of revenue.
The company highlighted a debt-free balance sheet, thyroid test volume growth, and operational metrics such as improved days sales outstanding and turnaround time. It also outlined a pancreatic cancer testing program in development and plans to add a Chief Scientific Officer in September 2026.